Macitentan reduces risk of mortality in PAH patients, study finds
LAVAL, Que. | Actelion Pharmaceuticals Canada has announced that a pivotal study with macitentan in patients with pulmonary arterial hypertension (PAH) has demonstrated a significant reduction in morbidity and mortality.
